Get the latest newsflashes from reMYND.

reMYND’s transgenic hTauP301L model of Alzheimer’s disease displays progressive neuronal loss correlating with development of Tau pathology
29-03-2017
Neuronal loss, a pathological hallmark of Alzheimer’s disease, is recapitulated in reMYND’s transgenic human hTauP301L mouse model.
Read more
reMYND’s transgenic hTauP301L model of Alzheimer’s disease displays progressive astrocytosis and microgliosis correlating with development of Tau pathology
14-03-2017
The role of microglia and astrocytes in Alzheimer’s disease and how these contribute to neuronal loss has gained increased interest over the past years.
Read more
reMYND receives grants from Flanders and Europe to advance break-through treatments in Epilepsy and Alzheimer’s
14-03-2017
reMYND NV today announced that it has received two grants from Flanders and Europe to advance break-through treatments in Epilepsy and Alzheimer’s respectively.
Read more
A novel transgenic mouse model showing the exacerbating interplay between Abeta- and Tau.P301S-driven pathology
10-06-2016

The interplay of Ab and Tau is still considered detrimental if not crucial for disease etiology and progression of Alzheimer’s Disease. You can now also assess the effects of your experimental Alzheimer’s Disease treatment on both amyloid- and tau pathology in the cross of our APP-london and Tau.P301S transgenic mouse models, in which APP-london aggravates the Tau-effect.  [/html]

Read more
reMYND signs the Statement in support of animal research and a transparent approach
22-04-2016
reMYND, has joined with 21 other organisations from across the life sciences sector in signing up to a declaration on openness on animal research.
Read more
reMYND to present on Biotechdag
19-10-2015
reMYND will be presenting on the research towards the treatment of Alheimers and diabetes worldwide.
Read more
Measuring cognition in reMYND’s Tau animal models
24-06-2015
reMYND’s Tau.P301L and Tau.P301S models feature progressive hyperphosphorylation of Tau with age.
Read more
IWT supports reMYND in developing a cure for Type 1 Diabetes
23-06-2015
reMYND announced that it has received a grant from IWT to assess the potential of its Diabetes program in curing Type 1 Diabetes Mellitus (T1DM).
Read more
Longitudinal imaging of Tau aggregates in vivo by two-photon imaging available in reMYND’s Tau.P301S model
06-03-2015
Two-photon imaging allows tracking the formation of Tau aggregates in the same brain-region of a live animal over the course of time.
Read more
Transgenic mouse model of combined Abeta and tau pathology
17-12-2014
The interplay of Abeta and Tau is considered detrimental if not crucial for disease etiology and progression of Alzheimer’s Disease.
Read more
Robust LTP measurements in Tau models
12-11-2014
LTP is gaining importance as a functional ex-vivo or even in-vivo read-out related to learning and memory.
Read more
LTP measurements available through reMYND
11-08-2014
reMYND now offers LTP measurements to allow clients to assess the effect of their experimental Alzheimer treatment.
Read more
reMYND’s novel diabetes treatment prevents – and even reverses – disease progression in pre-clinical diabetes models
05-05-2014
reMYND NV announced today that its experimental diabetes drug ReS39 has demonstrated a strong disease modifying effect in mice
Read more
Roche and reMYND's DDD enter into a strategic alliance to develop first-in-class disease-modifying treatments for Parkinson's and Alzheimer's disease
27-03-2014
Roche (SIX: RO, ROG; OTCQX: RHHBY) and reMYND today announced that they have entered into an agreement.
Read more
Roche presents preclinical efficacy data gathered in collaboration with reMYND’s CRO on a promising combo Alzheimer treatment
27-03-2014
Roche presents preclinical efficacy data gathered in collaboration with reMYND’s CRO on a promising combo Alzheimer treatment.
Read more
Tau.P301S model available at reMYND’s CRO for efficacy testing of Alzheimer treatments
27-03-2014
Over the last years, more and more tau-treatments are being assessed in mouse models for their potential to treat Alzheimer’s disease. One of the key challenges with many of the tau mouse models is the need for large numbers of animals due to their intrinsic variability.
Read more
Tulips for Parkinson’s
18-03-2014
For 2014, reMYND has dedicated the proceeds of its new year cards to the Vlaamse Parkinson Liga as part of StuBru’s Music-for-Life action.
Read more
The strategic alliance between Roche and reMYND is nominated for a Scrip Award
07-02-2014
The strategic Alliance between Roche and reMYND to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients is nominated for the Scrip Award “Best Partnership Alliance”.
Read more
reMYND’s Tau.P301L mice used to demonstrate efficacy of antibody treatment on behaviour and pathological read-outs
04-11-2013
In the last several years, Tau-directed therapies have gained more interest as a strategy for treating Alzheimer’s Disease.
Read more
BMS publishes paper in collaboration with reMYND showing dose-dependent effects of donepezil on brain Abeta and cognition in MWM
08-07-2013

“Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer’s disease”.

Read more
reMYND launches a project aimed at improving the predictability of preclinical Alzheimer models as part of the prestigious Marie-Curie International Training Network NPlast
06-09-2012
reMYND NV announced today its project in NPlast, a prestigious International Training Network funded by the European Commission that is to be launched April 27-28th 2012 at the Leibniz-Institut für Neurobiologie in Magdeburg, Germany.
Read more
Ajit Shetty strengthens reMYND’s Board of Directors
21-08-2012
reMYND NV today announced that its shareholders have elected Ajit Shetty to join the company’s 4-person Board as an Independent Director.
Read more
reMYND receives a positive tax ruling on the income from its Roche collaboration
31-01-2012
reMYND NV has received a positive ruling from the Belgian Tax Authorities. The ruling stipulates that the upfront license fee, all milestone payments and royalties linked to Roche Basel will qualify for the patent income deduction under Articles 205 WIB 92.
Read more
reMYND’s grant from the Michael J Fox Foundation in SciBX
17-08-2011
The Science-Business eXchange devoted an article to the role the Michael J Fox Foundation has been playing in PD therapeutics.
Read more
IWT helps to accelerate reMYND’s Diabetes program with a grant of 1.48 million EUR for 2011-2012
27-06-2011
reMYND NV today announced that it has received a grant of 1.48 million EUR to accelerate its Diabetes program.
Read more
reMYND’s CRO receives governmental grant for a continued innovation of its offering
09-05-2011
The governmental Agency for Innovation by Science and Technology (IWT) has approved a grant to reMYND’s Contract Research Organization.
Read more
reMYND's CRO announces quarterly digital Newsletter
08-02-2011
The prestigious Journal of Alzheimer's Disease publishes new data on reMYND's proprietary mouse models of Alzheimer's disease.
Read more
Review in Nature highlights reMYND's discovery platform
15-11-2010
The growing interest in targeting protein misfolding to therapeutically treat both rare and common diseases was featured in Nature Reviews Drug Discovery.
Read more
reMYND's CRO announces publication in the International Journal of Alzheimer's Disease
08-09-2010

New data on reMYND's proprietary mouse models of Alzheimer's disease: pathological hallmarks, clinical parallels, and value for drug testing.

Read more
reMYND and Amorfix announce agreement
06-07-2010
Amorfix Life Sciences Ltd. (TSX:AMF) and reMYND nv today announced the signing of a partnership agreement.
Read more
Ablynx and reMYND settle dispute amicably
02-06-2010
Ablynx nv [Euronext Brussels: ABLX] and reMYND nv announced today that they have reached a settlement.
Read more
reMYND receives a grant of 0.9 million EUR from IWT
10-12-2009
reMYND receives a grant of 0.9 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
Read more
reMYND receives license renewal from Schering-Plough for RadarScreen
18-11-2009
reMYND nv announced today that it has received the renewal of the non-exclusive license agreement with Schering-Plough.
Read more
reMYND receives award for Company with an exceptional relevance to society
21-09-2009
reMYND received 'the 1st Award for Company with an exceptional relevance to society'.
Read more
reMYND awarded by the Michael J. Fox Foundation
21-07-2009
reMYND is one of the nine biotech and pharmaceutical companies that have been awarded by the Michael J. Fox Foundation
Read more
reMYND signs license with BioPredic
10-01-2009

reMYND signs a license with BioPredic for commercialization RadarScreen as a diagnostic kit for experimental use in Europe and Japan.

Read more
reMYND receives a grant of almost 1 million EUR from IWT
10-12-2008
reMYND receives a grant of almost 1 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
Read more
reMYND's Lead Alzheimer drug demonstrates neuroprotection
15-11-2008
reMYND's Lead Alzheimer drug demonstrates neuroprotection in 2 transgenic animal models of TAU and Amyloid bèta pathology.
Read more
reMYND licenses highly innovative transgenic mouse models
20-08-2008
reMYND licenses highly innovative transgenic mouse models of Alzheimer's Disease TAU and Amyloid pathology from the University of Leuven.
Read more
reMYND installs world-class scientific advisory board
25-06-2008
reMYND installs world-class scientific advisory board with Parkinson's and Alzheimer's Disease experts.
Read more
Lead product for treating Parkinson's Disease demonstrates efficacy
15-03-2008
Lead product for treating Parkinson's Disease demonstrates efficacy in 3 different animal models of Parkinson's Disease.
Read more
reMYND signs license agreement
20-12-2007
reMYND signs a license agreement with another biotech company for their internal use of reMYND’s proprietary APPLon model.
Read more
reMYND's Parkinson's disease drug discovery program reaches breakthrough
26-03-2007
reMYND nv has reached a breakthrough in its drug discovery program aimed at identifying disease-modifying drugs for the treatment of Parkinson's disease.
Read more